Kintara Selling General Administrative vs Property Plant Equipment Analysis

KTRA Stock

USD 0.15 0.01 6.25%

Kintara Therapeutics financial indicator trend analysis is infinitely more than just investigating Kintara Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kintara Therapeutics is a good investment. Please check the relationship between Kintara Therapeutics Selling General Administrative and its Property Plant Equipment accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kintara Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Kintara Stock refer to our How to Trade Kintara Stock guide.

Selling General Administrative vs Property Plant Equipment

Selling General Administrative vs Property Plant Equipment Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kintara Therapeutics Selling General Administrative account and Property Plant Equipment. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Kintara Therapeutics' Selling General Administrative and Property Plant Equipment is -0.28. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Property Plant Equipment in the same time period over historical financial statements of Kintara Therapeutics, assuming nothing else is changed. The correlation between historical values of Kintara Therapeutics' Selling General Administrative and Property Plant Equipment is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of Kintara Therapeutics are associated (or correlated) with its Property Plant Equipment. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant Equipment has no effect on the direction of Selling General Administrative i.e., Kintara Therapeutics' Selling General Administrative and Property Plant Equipment go up and down completely randomly.

Correlation Coefficient

-0.28

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Selling General Administrative

Property Plant Equipment

Most indicators from Kintara Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kintara Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kintara Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Kintara Stock refer to our How to Trade Kintara Stock guide.At present, Kintara Therapeutics' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.0005, whereas Selling General Administrative is forecasted to decline to about 4.7 M.

	2021	2023	2024 (projected)
Research Development	15.2M	8.4M	8.0M
Depreciation And Amortization	60K	69K	72.5K

Research Development Depreciation And Amortization

Kintara Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Net Receivables	Other Current Liab	Short Long Term Debt Total	Other Current Assets	Other Liab	Net Tangible Assets	Non Current Assets Total	Good Will	Intangible Assets	Net Invested Capital	Net Working Capital
Total Assets		0.56	0.92	-0.95	-0.54	0.52	0.95	0.95	-0.16	-0.02	-0.2	0.48	0.37	0.99	0.61	0.13	0.63	0.01	0.79	-0.51	0.12	0.82	-0.05	-0.51	-0.03	0.42
Total Current Liabilities	0.56		0.41	-0.31	-0.96	0.99	0.32	0.32	0.17	-0.13	-0.41	0.95	0.31	0.51	0.08	-0.15	0.82	-0.5	0.64	-0.8	-0.63	0.71	0.49	-0.86	-0.76	-0.46
Total Stockholder Equity	0.92	0.41		-0.93	-0.38	0.38	0.92	0.92	-0.18	-0.23	-0.44	0.3	0.02	0.92	0.49	0.27	0.51	0.19	0.78	-0.48	0.28	0.72	-0.19	-0.46	0.12	0.53
Net Debt	-0.95	-0.31	-0.93		0.28	-0.26	-1.0	-1.0	0.13	0.01	0.07	-0.19	-0.31	-0.96	-0.64	-0.22	-0.51	-0.28	-0.65	0.36	-0.38	-0.66	0.29	0.35	-0.23	-0.59
Retained Earnings	-0.54	-0.96	-0.38	0.28		-0.97	-0.29	-0.29	-0.03	0.06	0.4	-0.98	-0.36	-0.48	-0.04	0.21	-0.72	0.47	-0.6	0.73	0.73	-0.72	-0.49	0.79	0.83	0.44
Accounts Payable	0.52	0.99	0.38	-0.26	-0.97		0.27	0.27	0.11	-0.14	-0.44	0.97	0.28	0.48	0.02	-0.12	0.76	-0.55	0.63	-0.8	-0.67	0.68	0.54	-0.85	-0.79	-0.49
Cash	0.95	0.32	0.92	-1.0	-0.29	0.27		1.0	-0.14	0.01	-0.05	0.2	0.34	0.96	0.65	0.22	0.51	0.26	0.65	-0.36	0.36	0.66	-0.27	-0.35	0.22	0.58
Cash And Short Term Investments	0.95	0.32	0.92	-1.0	-0.29	0.27	1.0		-0.14	0.01	-0.05	0.2	0.34	0.96	0.65	0.22	0.51	0.26	0.65	-0.36	0.36	0.66	-0.27	-0.35	0.22	0.58
Common Stock Total Equity	-0.16	0.17	-0.18	0.13	-0.03	0.11	-0.14	-0.14		-0.09	0.15	-0.01	0.03	-0.17	-0.08	-0.14	0.48	0.1	-0.16	-0.18	-0.1	-0.13	-0.1	-0.22	-0.14	-0.39
Common Stock Shares Outstanding	-0.02	-0.13	-0.23	0.01	0.06	-0.14	0.01	0.01	-0.09		0.58	-0.06	0.56	-0.02	0.21	-0.2	-0.07	0.01	-0.2	0.23	-0.03	-0.02	0.03	0.22	0.03	0.05
Non Current Liabilities Total	-0.2	-0.41	-0.44	0.07	0.4	-0.44	-0.05	-0.05	0.15	0.58		-0.4	0.65	-0.16	0.29	-0.19	-0.14	0.22	-0.52	0.46	0.22	-0.33	-0.22	0.44	0.3	0.07
Other Stockholder Equity	0.48	0.95	0.3	-0.19	-0.98	0.97	0.2	0.2	-0.01	-0.06	-0.4		0.33	0.42	-0.02	-0.21	0.66	-0.64	0.57	-0.7	-0.77	0.67	0.63	-0.76	-0.85	-0.49
Total Liab	0.37	0.31	0.02	-0.31	-0.36	0.28	0.34	0.34	0.03	0.56	0.65	0.33		0.36	0.52	-0.28	0.4	-0.05	0.12	-0.08	-0.21	0.36	0.17	-0.12	-0.21	-0.04
Total Current Assets	0.99	0.51	0.92	-0.96	-0.48	0.48	0.96	0.96	-0.17	-0.02	-0.16	0.42	0.36		0.58	0.21	0.58	0.03	0.78	-0.51	0.17	0.75	-0.08	-0.5	0.02	0.43
Common Stock	0.61	0.08	0.49	-0.64	-0.04	0.02	0.65	0.65	-0.08	0.21	0.29	-0.02	0.52	0.58		-0.11	0.37	0.31	0.41	0.16	0.43	0.59	-0.31	0.14	0.4	0.66
Net Receivables	0.13	-0.15	0.27	-0.22	0.21	-0.12	0.22	0.22	-0.14	-0.2	-0.19	-0.21	-0.28	0.21	-0.11		-0.25	0.18	0.37	-0.35	0.42	-0.3	-0.17	-0.24	0.31	0.14
Other Current Liab	0.63	0.82	0.51	-0.51	-0.72	0.76	0.51	0.51	0.48	-0.07	-0.14	0.66	0.4	0.58	0.37	-0.25		-0.1	0.53	-0.64	-0.3	0.74	0.12	-0.71	-0.45	-0.18
Short Long Term Debt Total	0.01	-0.5	0.19	-0.28	0.47	-0.55	0.26	0.26	0.1	0.01	0.22	-0.64	-0.05	0.03	0.31	0.18	-0.1		-0.14	0.26	0.62	-0.14	-0.8	0.3	0.61	0.54
Other Current Assets	0.79	0.64	0.78	-0.65	-0.6	0.63	0.65	0.65	-0.16	-0.2	-0.52	0.57	0.12	0.78	0.41	0.37	0.53	-0.14		-0.69	-0.03	0.7	0.12	-0.66	-0.19	0.21
Other Liab	-0.51	-0.8	-0.48	0.36	0.73	-0.8	-0.36	-0.36	-0.18	0.23	0.46	-0.7	-0.08	-0.51	0.16	-0.35	-0.64	0.26	-0.69		0.37	-0.41	-0.28	0.99	0.57	0.4
Net Tangible Assets	0.12	-0.63	0.28	-0.38	0.73	-0.67	0.36	0.36	-0.1	-0.03	0.22	-0.77	-0.21	0.17	0.43	0.42	-0.3	0.62	-0.03	0.37		-0.19	-0.65	0.44	0.97	0.79
Non Current Assets Total	0.82	0.71	0.72	-0.66	-0.72	0.68	0.66	0.66	-0.13	-0.02	-0.33	0.67	0.36	0.75	0.59	-0.3	0.74	-0.14	0.7	-0.41	-0.19		0.16	-0.47	-0.29	0.24
Good Will	-0.05	0.49	-0.19	0.29	-0.49	0.54	-0.27	-0.27	-0.1	0.03	-0.22	0.63	0.17	-0.08	-0.31	-0.17	0.12	-0.8	0.12	-0.28	-0.65	0.16		-0.31	-0.64	-0.54
Intangible Assets	-0.51	-0.86	-0.46	0.35	0.79	-0.85	-0.35	-0.35	-0.22	0.22	0.44	-0.76	-0.12	-0.5	0.14	-0.24	-0.71	0.3	-0.66	0.99	0.44	-0.47	-0.31		0.64	0.45
Net Invested Capital	-0.03	-0.76	0.12	-0.23	0.83	-0.79	0.22	0.22	-0.14	0.03	0.3	-0.85	-0.21	0.02	0.4	0.31	-0.45	0.61	-0.19	0.57	0.97	-0.29	-0.64	0.64		0.79
Net Working Capital	0.42	-0.46	0.53	-0.59	0.44	-0.49	0.58	0.58	-0.39	0.05	0.07	-0.49	-0.04	0.43	0.66	0.14	-0.18	0.54	0.21	0.4	0.79	0.24	-0.54	0.45	0.79

Click cells to compare fundamentals

Kintara Therapeutics Account Relationship Matchups

Kintara Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.9M	13.5M	15.9M	4.0M	4.6M	5.8M
Total Current Liabilities	2.7M	2.8M	4.0M	3.1M	3.5M	3.7M
Total Stockholder Equity	263.2K	10.6M	11.8M	731K	840.7K	798.6K
Net Debt	(2.4M)	(10.5M)	(11.8M)	(1.5M)	(1.4M)	(1.5M)
Retained Earnings	(69.7M)	(111.2M)	(136.4M)	(151.4M)	(136.2M)	(129.4M)
Accounts Payable	2.0M	2.2M	3.3M	2.8M	3.2M	3.4M
Cash	2.4M	10.5M	11.8M	1.5M	1.8M	1.7M
Cash And Short Term Investments	2.4M	10.5M	11.8M	1.5M	1.8M	1.7M
Common Stock Total Equity	23.0K	3.8K	8.6M	33K	38.0K	36.1K
Common Stock Shares Outstanding	208.9K	517.7K	974.0K	1.6M	1.5M	777.4K
Liabilities And Stockholders Equity	2.9M	13.5M	15.9M	4.0M	4.6M	5.8M
Non Current Liabilities Total	2.0M	182K	163K	166K	149.4K	141.9K
Other Stockholder Equity	65.1M	106.8M	135.5M	141.4M	162.7M	170.8M
Total Liab	2.7M	3.0M	4.2M	3.2M	3.7M	2.3M
Total Current Assets	2.9M	11.8M	13.3M	3.3M	3.8M	5.4M
Common Stock	11.5K	33K	66K	2K	2.3K	2.2K
Other Current Liab	663.9K	561K	721K	298K	342.7K	310.2K
Other Current Assets	355.6K	1.3M	1.5M	660K	759K	812.1K
Net Tangible Assets	(4.5M)	(4.4M)	(759K)	(9.9M)	(8.9M)	(8.5M)
Non Current Assets Total	87.1K	1.8M	2.7M	709K	815.4K	736.0K
Net Invested Capital	(4.5M)	(4.4M)	(759K)	(9.9M)	(8.9M)	(8.5M)
Net Working Capital	176.2K	9.0M	9.3M	188K	169.2K	160.7K
Capital Stock	4.8M	15.0M	12.6M	10.6M	12.2M	10.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Kintara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kintara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kintara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kintara Therapeutics Stock:

How To Invest In Kintara

Details

Is Kintara Stock a good investment?

Details

What is Kintara Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kintara Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Kintara Stock refer to our How to Trade Kintara Stock guide.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Complementary Tools for Kintara Stock analysis

When running Kintara Therapeutics' price analysis, check to measure Kintara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kintara Therapeutics is operating at the current time. Most of Kintara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kintara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kintara Therapeutics' price. Additionally, you may evaluate how the addition of Kintara Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Equity Valuation Check real value of public entities based on technical and fundamental data
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	CEOs Directory Screen CEOs from public companies around the world

Is Kintara Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kintara Therapeutics. If investors know Kintara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kintara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.22)

Return On Assets

(1.13)

Return On Equity

(3.29)

The market value of Kintara Therapeutics is measured differently than its book value, which is the value of Kintara that is recorded on the company's balance sheet. Investors also form their own opinion of Kintara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kintara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kintara Therapeutics' market value can be influenced by many factors that don't directly affect Kintara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kintara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kintara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kintara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kintara Selling General Administrative vs Property Plant Equipment Analysis

Selling General Administrative vs Property Plant Equipment

Selling General Administrative vs Property Plant Equipment Correlation Analysis

Correlation Coefficient

Selling General Administrative

Property Plant Equipment

Kintara Therapeutics fundamental ratios Correlations

Kintara Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kintara Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Kintara Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Accounts Payable	+ 0.99	Total Current Liabilities
Intangible Assets	+ 0.99	Other Liab
Other Stockholder Equity	+ 0.97	Accounts Payable
Net Invested Capital	+ 0.97	Net Tangible Assets

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Accounts Payable	- 0.97	Retained Earnings
Total Current Assets	- 0.96	Net Debt
Retained Earnings	- 0.96	Total Current Liabilities